|
BE792533A
(fr)
|
1971-12-09 |
1973-06-08 |
Int Chem & Nuclear Corp |
Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
|
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
CA2143491C
(en)
|
1994-03-01 |
2011-02-22 |
Yasumasa Ishida |
A novel peptide related to human programmed cell death and dna encoding it
|
|
JP2778921B2
(ja)
|
1994-11-18 |
1998-07-23 |
三共株式会社 |
イミダゾピラゾール誘導体
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
MX353234B
(es)
|
1999-01-15 |
2018-01-08 |
Genentech Inc |
Variantes de polipeptidos con función efectora alterada.
|
|
PL362804A1
(en)
|
1999-08-23 |
2004-11-02 |
Dana-Farber Cancer Institute |
Novel b7-4 molecules and uses therefor
|
|
HU228477B1
(en)
|
1999-08-23 |
2013-03-28 |
Dana Farber Cancer Inst Inc |
Pd-1, a receptor for b7-4, and uses therefor
|
|
PT1212422E
(pt)
|
1999-08-24 |
2007-04-30 |
Medarex Inc |
Anticorpos contra citla-4 humana e suas utilizações
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
CA2379421A1
(en)
|
1999-08-27 |
2001-03-08 |
Abbott Laboratories |
Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
|
|
ATE247657T1
(de)
|
1999-09-17 |
2003-09-15 |
Basf Ag |
Pyrazolopyrimidine als arzneimittel
|
|
CA2406993A1
(en)
|
2000-03-24 |
2001-09-27 |
Micromet Ag |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
|
WO2001079299A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
|
AU2001295041A1
(en)
|
2000-09-08 |
2002-03-22 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US20020094989A1
(en)
|
2000-10-11 |
2002-07-18 |
Hale Jeffrey J. |
Pyrrolidine modulators of CCR5 chemokine receptor activity
|
|
EP1334659B1
(en)
|
2000-11-15 |
2012-01-11 |
Ono Pharmaceutical Co., Ltd. |
Pd-1-lacking mouse and use thereof
|
|
DK1355919T3
(da)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
|
|
EP1347971B1
(en)
|
2000-12-21 |
2006-03-01 |
Bristol-Myers Squibb Company |
Thiazolyl inhibitors of tec family tyrosine kinases
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
PL206701B1
(pl)
|
2001-03-07 |
2010-09-30 |
Merck Patent Gmbh |
Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
|
|
ATE309997T1
(de)
|
2001-03-09 |
2005-12-15 |
Pfizer Prod Inc |
Entzündungshemmende benzimidazolverbindungen
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
JPWO2003004497A1
(ja)
|
2001-07-05 |
2004-10-28 |
住友製薬株式会社 |
新規複素環化合物
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
CN1771231B
(zh)
|
2002-08-26 |
2011-05-25 |
武田药品工业株式会社 |
钙受体调节性化合物及其用途
|
|
BRPI0313880B8
(pt)
|
2002-08-26 |
2021-05-25 |
Takeda Pharmaceuticals Co |
composto
|
|
NZ538996A
(en)
|
2002-10-31 |
2008-04-30 |
Genentech Inc |
Methods and compositions for increasing antibody production
|
|
AU2003288675B2
(en)
|
2002-12-23 |
2010-07-22 |
Medimmune Limited |
Antibodies against PD-1 and uses therefor
|
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
US20060183746A1
(en)
|
2003-06-04 |
2006-08-17 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
|
EP1651648A4
(en)
|
2003-07-29 |
2009-09-02 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
WO2005047290A2
(en)
|
2003-11-11 |
2005-05-26 |
Cellular Genomics Inc. |
Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
ES2387312T3
(es)
|
2004-09-22 |
2012-09-20 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos IgG4 humanos estabilizados
|
|
EP1812442A2
(en)
|
2004-11-10 |
2007-08-01 |
CGI Pharmaceuticals, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
|
|
CA2591413A1
(en)
|
2004-12-16 |
2006-06-22 |
Vertex Pharmaceuticals Incorporated |
Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
TW200716551A
(en)
|
2005-03-10 |
2007-05-01 |
Cgi Pharmaceuticals Inc |
Certain substituted amides, method of making, and method of use thereof
|
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
SG10201702670VA
(en)
|
2005-06-08 |
2017-06-29 |
Dana Farber Cancer Inst Inc |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
|
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
EP1919891B1
(en)
|
2005-08-29 |
2012-03-07 |
Vertex Pharmaceuticals Incorporated |
3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
|
|
WO2007027729A1
(en)
|
2005-08-29 |
2007-03-08 |
Vertex Pharmaceuticals Incorporated |
3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
|
|
WO2007026720A1
(ja)
|
2005-08-31 |
2007-03-08 |
Taisho Pharmaceutical Co., Ltd. |
縮環ピラゾール誘導体
|
|
WO2007026950A1
(en)
|
2005-09-01 |
2007-03-08 |
Astellas Pharma Inc. |
Pyridazinone derivatives used for the treatment of pain
|
|
ZA200804679B
(en)
|
2005-12-08 |
2010-02-24 |
Millenium Pharmaceuticals Inc |
Bicyclic compounds with kinase inhibitory activity
|
|
CA2636696A1
(en)
|
2006-01-13 |
2007-08-02 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
|
RU2429244C2
(ru)
|
2006-03-23 |
2011-09-20 |
Байоарктик Ньюросайенс Аб |
Улучшенные селективные в отношении протофибрилл антитела и их применение
|
|
US7442808B2
(en)
|
2006-05-15 |
2008-10-28 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
MX2008014450A
(es)
|
2006-05-18 |
2009-03-09 |
Mannkind Corp |
Inhibidores de cinasa intracelular.
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
吡咯并嘧啶化合物及其用途
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
PE20080839A1
(es)
|
2006-09-11 |
2008-08-23 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
|
|
PE20081370A1
(es)
|
2006-09-11 |
2008-11-28 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
|
|
JP2010502751A
(ja)
|
2006-09-11 |
2010-01-28 |
シージーアイ ファーマシューティカルズ，インコーポレイティド |
キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
|
|
AR063946A1
(es)
|
2006-09-11 |
2009-03-04 |
Cgi Pharmaceuticals Inc |
Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
HUE025459T2
(hu)
|
2006-09-22 |
2016-05-30 |
Pharmacyclics Inc |
A Bruton-féle tirozin-kináz inhibitorai
|
|
KR20090063240A
(ko)
|
2006-10-06 |
2009-06-17 |
아이알엠 엘엘씨 |
단백질 키나제 억제제 및 그의 사용 방법
|
|
EP2089391B1
(en)
|
2006-11-03 |
2013-01-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
WO2008116064A2
(en)
|
2007-03-21 |
2008-09-25 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
|
|
WO2008144253A1
(en)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
|
EP2666787B1
(en)
|
2007-05-31 |
2022-02-09 |
Genmab A/S |
STABLE IgG4 ANTIBODIES
|
|
WO2008156712A1
(en)
|
2007-06-18 |
2008-12-24 |
N. V. Organon |
Antibodies to human programmed death receptor pd-1
|
|
US9243052B2
(en)
|
2007-08-17 |
2016-01-26 |
Daniel Olive |
Method for treating and diagnosing hematologic malignancies
|
|
CL2008002793A1
(es)
|
2007-09-20 |
2009-09-04 |
Cgi Pharmaceuticals Inc |
Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
TWI475996B
(zh)
|
2007-10-19 |
2015-03-11 |
Celgene Avilomics Res Inc |
雜芳基化合物及其用途
|
|
ES2499017T3
(es)
|
2007-10-23 |
2014-09-26 |
F. Hoffmann-La Roche Ag |
Nuevos inhibidores de quinasa
|
|
WO2009077334A1
(en)
|
2007-12-14 |
2009-06-25 |
F. Hoffmann-La Roche Ag |
Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
|
|
EP2242749B1
(en)
|
2008-02-05 |
2013-04-10 |
F. Hoffmann-La Roche AG |
Novel pyridinones and pyridazinones
|
|
KR101666229B1
(ko)
|
2008-02-08 |
2016-10-14 |
메디뮨 엘엘씨 |
Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
EP2297105B1
(en)
|
2008-05-06 |
2015-09-02 |
Gilead Connecticut, Inc. |
Substituted amides, method of making, and use as btk inhibitors
|
|
KR101892989B1
(ko)
|
2008-06-27 |
2018-08-30 |
셀젠 카르 엘엘씨 |
헤테로아릴 화합물 및 이의 용도
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
CA2728683C
(en)
|
2008-07-02 |
2017-05-02 |
F.Hoffmann-La Roche Ag |
Novel phenylpyrazinones as kinase inhibitors
|
|
EP2307413B1
(en)
|
2008-07-15 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Novel phenyl-imidazopyridines and pyridazines
|
|
CN102159214A
(zh)
|
2008-07-16 |
2011-08-17 |
药品循环公司 |
用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
|
|
MX2010013190A
(es)
|
2008-07-18 |
2010-12-20 |
Hoffmann La Roche |
Fenilimidazopirazinas novedosas.
|
|
CN102164604A
(zh)
|
2008-07-24 |
2011-08-24 |
百时美施贵宝公司 |
用作激酶调节剂的稠合杂环化合物
|
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Ｐｄ-１ 길항제 및 그의 사용 방법
|
|
WO2010028236A1
(en)
|
2008-09-05 |
2010-03-11 |
Avila Therapeutics, Inc. |
Algorithm for designing irreversible inhibitors
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
PE20110828A1
(es)
|
2008-10-31 |
2011-11-22 |
Genentech Inc |
Compuestos de pirazolopirimidina como inhibidores de jak
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
US8598174B2
(en)
|
2008-11-12 |
2013-12-03 |
Genetech, Inc. |
Pyridazinones, method of making, and method of use thereof
|
|
DK2370593T3
(en)
|
2008-11-28 |
2016-07-04 |
Univ Emory |
A method for determining the effect of PD-1 Antagonists
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
EP4331604B1
(en)
|
2008-12-09 |
2025-03-05 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010068810A2
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
WO2010068788A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Heterocyclic amides as btk inhibitors
|
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
ES2443948T3
(es)
|
2008-12-19 |
2014-02-21 |
Bristol-Myers Squibb Company |
Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
|
|
US20100197924A1
(en)
|
2008-12-22 |
2010-08-05 |
Millennium Pharmaceuticals, Inc. |
Preparation of aminotetralin compounds
|
|
WO2010080712A2
(en)
|
2009-01-06 |
2010-07-15 |
Dana Farber Cancer Institute |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
EP2421854B1
(en)
|
2009-04-24 |
2014-07-23 |
F.Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
|
EP2424368B1
(en)
|
2009-04-29 |
2014-12-31 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
|
JP2012529535A
(ja)
|
2009-06-12 |
2012-11-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼモジュレーターとして有用なニコチンアミド化合物
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2011019780A1
(en)
|
2009-08-11 |
2011-02-17 |
Bristol-Myers Squibb Company |
Azaindazoles as btk kinase modulators and use thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
|
PT2473049T
(pt)
|
2009-09-04 |
2019-03-04 |
Sunesis Pharmaceuticals Inc |
Inibidores de tirosina quinase de bruton
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
JP5774595B2
(ja)
|
2009-10-28 |
2015-09-09 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｇｌｐ−１ｒ抗体及びそれらの使用
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
RS61136B1
(sr)
|
2010-02-19 |
2020-12-31 |
Xencor Inc |
Novi ctla4-ig imunoadhezini
|
|
CN102971340A
(zh)
|
2010-03-29 |
2013-03-13 |
酵活有限公司 |
具有增强的或抑制的效应子功能的抗体
|
|
AU2011249912A1
(en)
|
2010-05-07 |
2012-11-29 |
Genentech, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
|
AU2011260961B9
(en)
|
2010-05-31 |
2015-02-26 |
Ono Pharmaceutical Co., Ltd. |
Purinone derivative
|
|
JP5841998B2
(ja)
|
2010-06-03 |
2016-01-13 |
ファーマサイクリックス，インク． |
ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
|
|
EP2582668B1
(en)
|
2010-06-16 |
2016-01-13 |
Bristol-Myers Squibb Company |
Carboline carboxamide compounds useful as kinase inhibitors
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
NZ605988A
(en)
|
2010-06-23 |
2014-11-28 |
Hanmi Science Co Ltd |
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US20120053189A1
(en)
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
KR20130099040A
(ko)
|
2010-08-10 |
2013-09-05 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Ｂｔｋ 억제제의 베실레이트 염
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
BR112013007499A2
(pt)
|
2010-09-01 |
2016-07-12 |
Genentech Inc |
piridazinonas - métodos de criação e usos
|
|
CN103189369B
(zh)
|
2010-09-01 |
2016-08-24 |
吉利德康涅狄格有限公司 |
吡啶酮/吡嗪酮、其制备方法及使用方法
|
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
|
US8969526B2
(en)
|
2011-03-29 |
2015-03-03 |
Roche Glycart Ag |
Antibody Fc variants
|
|
CN103429264A
(zh)
|
2011-03-31 |
2013-12-04 |
默沙东公司 |
针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
|
|
US8703767B2
(en)
|
2011-04-01 |
2014-04-22 |
University Of Utah Research Foundation |
Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
|
|
CA2760174A1
(en)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Protein kinase inhibitors and uses thereof
|
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
|
JP2014511894A
(ja)
|
2011-04-20 |
2014-05-19 |
グラクソ グループ リミテッド |
抗結核化合物としてのテトラヒドロピラゾロ［１，５‐ａ］ピリミジン
|
|
ES2590491T3
(es)
|
2011-05-17 |
2016-11-22 |
F. Hoffmann-La Roche Ag |
Inhibidores de la tirosina quinasa de Bruton
|
|
KR102027598B1
(ko)
|
2011-05-17 |
2019-10-01 |
프린시피아 바이오파마, 인코퍼레이티드 |
타이로신 키나아제 저해제
|
|
WO2012158810A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
PL2718322T3
(pl)
|
2011-06-06 |
2019-07-31 |
Novo Nordisk A/S |
Lecznicze przeciwciała
|
|
SG194219A1
(en)
|
2011-06-10 |
2013-11-29 |
Merck Patent Gmbh |
Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
|
|
AU2012273955A1
(en)
|
2011-06-22 |
2014-01-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
|
US9233111B2
(en)
|
2011-07-08 |
2016-01-12 |
Novartis Ag |
Pyrrolo pyrimidine derivatives
|
|
TWI654994B
(zh)
|
2011-08-01 |
2019-04-01 |
建南德克公司 |
利用ｐｄ－１軸結合拮抗劑及ｍｅｋ抑制劑治療癌症之方法
|
|
ES2808152T3
(es)
|
2011-11-28 |
2021-02-25 |
Merck Patent Gmbh |
Anticuerpos anti-PD-L1 y usos de los mismos
|
|
KR20240096553A
(ko)
|
2012-01-12 |
2024-06-26 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
CN104204204A
(zh)
|
2012-02-09 |
2014-12-10 |
中外制药株式会社 |
抗体的Fc区变异体
|
|
JP6391564B2
(ja)
|
2012-04-30 |
2018-09-19 |
メディミューン，エルエルシー |
低減されたエフェクター機能及び延長された半減期を有する分子、組成物、並びにそれらの使用
|
|
EP2850102A1
(en)
|
2012-05-15 |
2015-03-25 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
MX2014015744A
(es)
|
2012-07-03 |
2015-06-05 |
Janssen Sciences Ireland Uc |
Anticuerpos a-beta de epítopo de terminal c y central.
|
|
WO2014055897A2
(en)
|
2012-10-04 |
2014-04-10 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
WO2014100490A1
(en)
|
2012-12-19 |
2014-06-26 |
Adimab, Llc |
Multivalent antibody analogs, and methods of their preparation and use
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
SI2840892T1
(en)
|
2013-02-20 |
2018-08-31 |
Regeneron Pharmaceuticals, Inc. |
Animals other than humans with modified immunoglobulin heavy chain sequences
|
|
KR20150127591A
(ko)
|
2013-03-15 |
2015-11-17 |
리제너론 파아마슈티컬스, 인크. |
Il-33 길항제 및 이의 용도
|
|
KR101793807B1
(ko)
|
2013-04-25 |
2017-11-03 |
베이진 엘티디 |
단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물
|
|
CA2913977C
(en)
|
2013-05-31 |
2022-11-29 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
US20150005277A1
(en)
|
2013-06-28 |
2015-01-01 |
Beigene, Ltd. |
Protein Kinase Inhibitors and Uses Thereof
|
|
EP2832358A1
(en)
*
|
2013-08-02 |
2015-02-04 |
Bionsil S.r.l. |
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
|
|
AU2013400609B9
(en)
|
2013-09-13 |
2020-03-05 |
Beigene Switzerland Gmbh |
Anti-PD1 antibodies and their use as therapeutics and diagnostics
|
|
AU2014339816B2
(en)
|
2013-10-25 |
2020-05-28 |
Pharmacyclics Llc |
Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
CN106687446B
(zh)
|
2014-07-18 |
2020-04-28 |
百济神州(北京)生物科技有限公司 |
作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
PT3179992T
(pt)
*
|
2014-08-11 |
2022-07-12 |
Acerta Pharma Bv |
Combinações terapêuticas de um inibidor de btk, um inibidor de pd-1 e/ou um inibidor de pd-l1
|
|
WO2016025720A1
(en)
|
2014-08-14 |
2016-02-18 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
TW201625304A
(zh)
|
2014-10-24 |
2016-07-16 |
美國禮來大藥廠 |
泌尿上皮癌之療法
|
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
|
SG11201704808VA
(en)
*
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
HRP20230305T1
(hr)
|
2014-12-24 |
2023-05-26 |
Principia Biopharma Inc. |
Pripravci za ileo-jejunalnu dostavu lijeka
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
KR102616762B1
(ko)
|
2015-03-18 |
2023-12-20 |
아비나스 오퍼레이션스, 인코포레이티드 |
타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들
|
|
CN104777137B
(zh)
|
2015-03-25 |
2018-06-19 |
深圳市贝沃德克生物技术研究院有限公司 |
生物标志物检测用光谱位置调节装置
|
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
CN108136044B
(zh)
|
2015-06-04 |
2021-08-10 |
阿尔维纳斯运营股份有限公司 |
基于酰亚胺的蛋白水解调节剂和相关使用方法
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
WO2017011590A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
ES2900482T3
(es)
|
2015-10-01 |
2022-03-17 |
Gilead Sciences Inc |
Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer
|
|
RU2018120330A
(ru)
|
2015-11-02 |
2019-12-04 |
Йейл Юниверсити |
Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
|
|
WO2017182418A1
(en)
|
2016-04-20 |
2017-10-26 |
Glaxosmithkline Intellectual Property Development Limited |
Conjugates comprising ripk2 inhibitors
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017201449A1
(en)
|
2016-05-20 |
2017-11-23 |
Genentech, Inc. |
Protac antibody conjugates and methods of use
|
|
WO2017214491A1
(en)
|
2016-06-09 |
2017-12-14 |
Blinkbio, Inc. |
Silanol based therapeutic payloads
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
JP6993056B2
(ja)
|
2016-07-05 |
2022-02-15 |
ベイジーン リミテッド |
癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
|
|
JP7402685B2
(ja)
|
2016-08-16 |
2023-12-21 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
（ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
|
|
GB201614134D0
(en)
|
2016-08-18 |
2016-10-05 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
ES2971881T3
(es)
|
2016-08-19 |
2024-06-10 |
Beigene Switzerland Gmbh |
Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
|
|
IL264970B2
(en)
|
2016-08-26 |
2024-12-01 |
Beigene Ltd |
ANTI–TIM–3 antibodies and their use
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CA3087528C
(en)
|
2016-09-15 |
2024-01-30 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018059437A1
(en)
|
2016-09-27 |
2018-04-05 |
Beigene, Ltd. |
Treatment cancers using combination comprising parp inhibitors
|
|
RS64208B1
(sr)
|
2016-10-11 |
2023-06-30 |
Arvinas Operations Inc |
Jedinjenja i metode za ciljanu degradaciju androgenog receptora
|
|
CA3039930A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
|
JP7038712B2
(ja)
|
2016-11-22 |
2022-03-18 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用法
|
|
EP3544957B1
(en)
|
2016-11-22 |
2024-05-29 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
CN110869765A
(zh)
*
|
2017-04-20 |
2020-03-06 |
Adc治疗有限公司 |
组合疗法
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
CN110997677A
(zh)
|
2017-08-12 |
2020-04-10 |
百济神州有限公司 |
具有改进的双重选择性的Btk抑制剂
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
EP3749366A4
(en)
|
2018-02-09 |
2021-11-10 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR UROTHELIAL CARCINOMA
|
|
GB201803746D0
(en)
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|
|
CA3093847A1
(en)
|
2018-03-21 |
2019-09-26 |
Mei Pharma, Inc. |
Combination therapy
|
|
JP2022538214A
(ja)
|
2019-06-10 |
2022-09-01 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
ブルトン型チロシンキナーゼ阻害剤を含む経口固体錠剤及びその調製方法
|
|
CN113950327A
(zh)
|
2019-06-10 |
2022-01-18 |
百济神州瑞士有限责任公司 |
口服胶囊剂及其制备方法
|
|
WO2021018018A1
(en)
|
2019-07-26 |
2021-02-04 |
Beigene, Ltd. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
|